Drugs / Meningococcal ABCWY Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02946385 | Nov 2016 → Feb 2018 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-04-16 | GlaxoSmithKline | GSK’s 5-in-1 meningococcal ABCWY vaccine candidate accepted for regulatory review by US FDA gsk.com ↗ |
| 2023-05-12 | GlaxoSmithKline | GSK presents pivotal data at ESPID confirming effectiveness of its 5-in-1 meningococcal ABCWY vaccine candidate, with demonstrated coverage against a panel of 110 MenB strains gsk.com ↗ |
| 2023-03-14 | GlaxoSmithKline | GSK announces positive pivotal phase III data for 5-in-1 Meningococcal ABCWY vaccine candidate gsk.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Meningococcal ABCWY Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02946385 ↗ |
| Modality | Vaccine | “Meningococcal ABCWY Vaccine” NCT02946385 ↗ |